Search

Displaying results 4391 - 4400 of 10000 in total
  1. Drug

    Butylated hydroxytoluene

    go.drugbank.com/drugs/DB16863
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Cadralazine

    go.drugbank.com/drugs/DB13452
    Experimental

    Categories: Arteriolar Smooth Muscle, Agents Acting On
  3. Drug

    Glycocyamine

    go.drugbank.com/drugs/DB02751
    Experimental

    Synonyms: N-amidinoglycine, N-(aminoiminomethyl)glycineCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in vitro. … When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle strength and extends survival time.

  5. Drug

    Mitemcinal

    go.drugbank.com/drugs/DB06587
    Investigational

    Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.

  6. Drug

    AVI-4557

    go.drugbank.com/drugs/DB05447
    Experimental

    AVI-4557 is an oral antisense compound that selectively inhibits the metabolic enzyme cytochrome P450 3A4 (CYP), a liver enzyme responsible for the metabolism or breakdown of approximately half of currently … in clearance and an increase in maximal blood concentration (Cmax).

  7. Drug

    Potassium acetate

    go.drugbank.com/drugs/DB14498
    Approved

    Mixtures: AMINOPLASMAL® 10% E, AMINOPLASMAL® 10% E
  8. Drug

    Potassium sulfate

    go.drugbank.com/drugs/DB14499
    Approved

  9. Drug

    VSF-173

    go.drugbank.com/drugs/DB05753
    Investigational

    VSF-173 is an oral small molecule. It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect. … Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive sleepiness.

  10. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].